XML 36 R21.htm IDEA: XBRL DOCUMENT v3.23.2
Business Segments and Geographic Information
 9 Months Ended
Jul. 01, 2023
Segment Reporting [Abstract]  
Business Segments and Geographic Information Business Segments and Geographic InformationThe Company has four reportable segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The Company measures and evaluates its reportable segments based on segment revenues and operating income adjusted to exclude the effect of non-cash charges (such as intangible asset amortization expense, and goodwill and intangible asset impairment charges), transaction and integration expenses for acquisitions, restructuring, consolidation and divestiture charges, litigation charges, and other one-time or unusual items.
Identifiable assets for the reportable segments consist of inventories, intangible assets, goodwill, and property, plant and equipment. The Company fully allocates depreciation expense to its reportable segments. The Company has presented all other identifiable assets as corporate assets. There were no inter-segment revenues during the three and nine months ended July 1, 2023 and June 25, 2022. Segment information is as follows:

 Three Months EndedNine Months Ended
 July 1,
2023		June 25,
2022		July 1,
2023		June 25,
2022
Total revenues:
Diagnostics$439.7 $560.1 $1,463.6 $2,497.6 
Breast Health360.3 282.8 1,079.9 952.7 
GYN Surgical157.3 138.1 456.2 389.6 
Skeletal Health27.1 21.7 85.4 69.7 
$984.4 $1,002.7 $3,085.1 $3,909.6 
Income (Loss) from operations:
Diagnostics$(113.5)$175.0 $142.8 $1,247.4 
Breast Health63.3 32.0 233.7 163.1 
GYN Surgical48.5 60.1 149.6 92.4 
Skeletal Health3.1 (3.2)9.8 (3.6)
$1.4 $263.9 $535.9 $1,499.3 
Depreciation and amortization:
Diagnostics$56.8 $67.8 $172.9 $205.4 
Breast Health12.2 16.9 38.7 45.5 
GYN Surgical11.9 24.7 35.8 72.1 
Skeletal Health0.3 0.2 0.5 0.5 
$81.2 $109.6 $247.9 $323.5 
Capital expenditures:
Diagnostics$22.6 $19.8 $58.7 $77.3 
Breast Health8.0 2.2 22.0 9.2 
GYN Surgical4.5 2.8 11.2 6.9 
Skeletal Health— 0.1 0.2 0.3 
Corporate1.4 0.8 5.6 1.9 
$36.5 $25.7 $97.7 $95.6 
 
July 1,
2023		September 24,
2022
Identifiable assets:
Diagnostics$2,696.9 $2,881.7 
Breast Health1,216.8 1,245.8 
GYN Surgical1,465.8 1,461.5 
Skeletal Health26.3 27.5 
Corporate3,932.1 3,454.7 
$9,337.9 $9,071.2 

The Company had no customers that represented greater than 10% of consolidated revenues during the three and nine months ended July 1, 2023 and June 25, 2022.

The Company operates in the major geographic areas noted in the below chart. Revenue data is based upon customer location. Other than the United States, no single country accounted for more than 10% of consolidated revenues. The Company’s sales in Europe are predominantly derived from the United Kingdom, Germany, France, Spain, Italy and the Netherlands. The Company’s sales in Asia-Pacific are predominantly derived from China, Australia and Japan. The “Rest of World” designation includes Canada, Latin America and the Middle East.
Revenues by geography as a percentage of total revenues were as follows:
 
 Three Months EndedNine Months Ended
 July 1,
2023		June 25,
2022		July 1,
2023		June 25,
2022
United States76.2 %73.3 %75.9 %70.1 %
Europe13.1 %16.4 %13.9 %19.2 %
Asia-Pacific6.4 %7.1 %6.2 %7.7 %
Rest of World4.3 %3.2 %4.0 %3.0 %
100.0 %100.0 %100.0 %100.0 %